Eli Lilly’s weight loss drug Zepbound led to significantly greater weight loss than Novo Nordisk’s Wegovy in a 72-week, head-to-head clinical trial, according to findings published in The New England ...

Eli Lilly's tirzepatide leads to 50% more weight loss compared to Novo Nordisk's semaglutide in 72-week study.

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average ... who led the study and presented the findings Sunday at the European Congress on Obesity in Spain.

As more doctors and patients turn to the latest weight-loss drugs, researchers are trying to figure out which drug is right ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...